OGC
NAGE

Oak Grove Capital’s Niagen Bioscience NAGE Stock Holding History

Oak Grove Capital’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,000
Closed -$21K – 163
2018
Q3 		$21K Hold
5,000
– – 0.02% 99
2018
Q2 		$19K Hold
5,000
– – 0.02% 95
2018
Q1 		$21K Buy
+5,000
New +$26.2K 0.02% 95

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Oak Grove Capital's NAGE Position: Q4 2018 in Review

Oak Grove Capital sold out of Niagen Bioscience (NAGE) in Q4 2018, closing a stake of 5,000 shares — an estimated $21K sold.

Oak Grove Capital first reported a position in NAGE in Q1 2018 and held it in 3 quarters. The position peaked at $21K in Q3 2018. 61 funds tracked by Wall St. Rank hold NAGE as of Q4 2018.

  • Oak Grove Capital reported no remaining Niagen Bioscience position as of Q4 2018 after selling out during the quarter.
  • Oak Grove Capital sold 5,000 Niagen Bioscience shares in Q4 2018, an estimated $21K.
  • Oak Grove Capital first reported a position in Niagen Bioscience in Q1 2018 and held it in 3 quarters.
  • Oak Grove Capital's Niagen Bioscience position peaked at $21K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2018.

Based on Oak Grove Capital's 13F filing for Q4 2018, filed 15 Feb 2019.